Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.

Antibiotics, Antitubercular / pharmacology DNA-Directed RNA Polymerases / genetics Drug Resistance, Bacterial / genetics Escherichia coli / drug effects Escherichia coli Proteins / genetics Humans Microbial Sensitivity Tests Mycobacterium smegmatis / drug effects RNA Polymerase II / genetics Rifabutin / pharmacology Rifampin / analogs & derivatives Substandard Drugs / adverse effects
Escherichia coli Mycobacterium smegmatis antimicrobial resistance rifampin rpoB substandard medicines tuberculosis

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
01 2019
Historique:
received: 10 06 2018
accepted: 31 10 2018
pubmed: 7 11 2018
medline: 29 1 2020
entrez: 7 11 2018
Statut: epublish

Résumé

Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs. Rifampin resistance is a critical concern for tuberculosis treatment. While subtherapeutic doses of medicine are known to select for antibiotic resistance, the effect of drug degradation products on the evolution of resistance is unknown. Here, we demonstrate that substandard drugs that contain degraded active pharmaceutical ingredients select for gene alterations that confer resistance to standard drugs. We generated drug-resistant

Identifiants

DOI: 10.1128/AAC.01243-18 PMID: 30397062 PMC: PMC6325213
pubmed: 30397062
pii: AAC.01243-18
doi: 10.1128/AAC.01243-18
pmc: PMC6325213
pii:
doi:

Substances chimiques

Antibiotics, Antitubercular 0
Escherichia coli Proteins 0
Substandard Drugs 0
rpoB protein, E coli 0
Rifabutin 1W306TDA6S
RNA Polymerase II EC 2.7.7.-
DNA-Directed RNA Polymerases EC 2.7.7.6
Rifampin VJT6J7R4TR
rifapentine XJM390A33U

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM008541
Pays : United States

Informations de copyright

Copyright © 2018 American Society for Microbiology.

Références

Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Toxicol Lett. 1983 Jul;17(3-4):301-6
pubmed: 6137887
J Clin Microbiol. 2012 Jan;50(1):81-5
pubmed: 22075601
N Engl J Med. 2015 Nov 26;373(22):2149-60
pubmed: 26605929
Lancet Infect Dis. 2012 Jun;12(6):488-96
pubmed: 22632187
Antimicrob Agents Chemother. 2013 Feb;57(2):893-900
pubmed: 23208715
Int J Tuberc Lung Dis. 2008 Aug;12(8):869-77
pubmed: 18647445
J Antimicrob Chemother. 2009 Aug;64(2):259-62
pubmed: 19520715
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4324-32
pubmed: 27161646
Nat Genet. 2013 Oct;45(10):1183-9
pubmed: 23995135
Int J Tuberc Lung Dis. 2013 Mar;17(3):308-11
pubmed: 23321423
Mol Cell. 2010 Feb 12;37(3):311-20
pubmed: 20159551
BMJ. 2003 Nov 15;327(7424):1126
pubmed: 14615319
Trends Pharmacol Sci. 2010 Mar;31(3):99-101
pubmed: 20117849
J Clin Microbiol. 2001 Jan;39(1):107-10
pubmed: 11136757
Int J Tuberc Lung Dis. 2004 Apr;8(4):500-3
pubmed: 15141745
Front Microbiol. 2017 Sep 14;8:1768
pubmed: 28959248
Clin Immunol Immunopathol. 1988 Jan;46(1):162-6
pubmed: 3275509
Antimicrob Agents Chemother. 2009 Mar;53(3):849-62
pubmed: 19075046
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7
pubmed: 9661035
Cell. 2001 Mar 23;104(6):901-12
pubmed: 11290327
J Infect. 2017 Mar;74(3):260-271
pubmed: 27998752
J Pharm Biomed Anal. 2003 Mar 10;31(3):607-12
pubmed: 12615251
Am J Trop Med Hyg. 2016 May 4;94(5):993-1001
pubmed: 26951346
Lancet. 2001 Jun 16;357(9272):1933-6
pubmed: 11425415
J Clin Microbiol. 2009 Sep;47(9):2744-50
pubmed: 19721079
J Mol Biol. 1988 Jul 5;202(1):45-58
pubmed: 3050121
Br J Clin Pharmacol. 2014 Aug;78(2):218-43
pubmed: 24286459
Mol Biol Evol. 2014 Sep;31(9):2387-401
pubmed: 24962091
Emerg Microbes Infect. 2014 Mar;3(3):e17
pubmed: 26038512
J Pharm Biomed Anal. 2017 Jan 5;132:17-23
pubmed: 27693756
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S347-50; discussion S351-2
pubmed: 10593716
Antimicrob Agents Chemother. 2014;58(1):590-2
pubmed: 24145520
Xenobiotica. 1976 Jan;6(1):21-32
pubmed: 5822
Antimicrob Agents Chemother. 2005 Jun;49(6):2200-9
pubmed: 15917513
J Clin Microbiol. 2014 Jun;52(6):2157-62
pubmed: 24740074

Auteurs

Zohar B Weinstein (ZB)

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA.

Muhammad H Zaman (MH)

Howard Hughes Medical Institute, Boston University, Boston, Massachusetts, USA Zaman@bu.edu.
Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Antibiotiques antituberculeux › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Nucleotidyltransferases › RNA nucleotidyltransferases › DNA-directed RNA polymerases › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › Protéines Escherichia coli › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobactéries non tuberculeuses › Mycobacterium smegmatis › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Nucleotidyltransferases › RNA nucleotidyltransferases › DNA-directed RNA polymerases › RNA polymerase II › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifabutine › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Evolution of Rifampin Resistance in...
questionsmedicales.fr › Préparations pharmaceutiques › Médicaments non conformes aux normes › Evolution of Rifampin Resistance in...